

VIRTUAL MEETING INVITATION

A Pharmacist's Perspective: Decision Making for Antiviral Prescribing for Covid 19 Patients | **Wednesday 20th September 2023**
13:00 - 14:00

The Adverse Event reporting statement and Prescribing Information for Pfizer medicines that will be referenced at the meeting can be found at the end of this document. This document is intended to be read electronically.

PAXLOVID® ▼ (nirmatrelvir/ritonavir) has received Conditional Marketing Authorisation (CMA) for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.¹ A Conditional Marketing Authorisation (CMA) means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year, and the product information will be updated as necessary.¹

Dear Healthcare Professional,

You are invited to attend a promotional meeting organised and funded by Pfizer Ltd which may include reference to Pfizer medicines relevant to the agenda topics. This meeting is intended for healthcare professionals resident in Great Britain. This meeting is also available to join via MS Teams. This invitation is for your personal use. Please do not forward to others.

PFIZERPRO HCP EVENTS:

If you wish to keep up to date with other Pfizer organised promotional educational meetings in your area that may be of interest to you as a healthcare professional resident in the UK,
[please click here](#)

EVENT AGENDA

12:45 - 13:00 **Joining & Registration**

13:00 - 13:45 **Advancing Covid-19 Care**

Mr Kevin Hazelwood

13:45 - 14:00 **Questions & Answers**

Mr Kevin Hazelwood

14:00 **Meeting Close**

HOSTED BY

Kerry Murphy

Senior Healthcare Partnership Manager

SPEAKERS

Mr Kevin Hazelwood

Lead Pharmacist - Emergency Service

East & North Hertfordshire NHS Trust

This promotional meeting is organised and funded by Pfizer Ltd. Please note that, under the law and the ABPI Code of Practice, Pfizer may only provide hospitality and/or promote its medicines to members of the healthcare professions and other relevant decision makers. Therefore, no unqualified person (e.g., medical students, non-medical spouses, partners) may be invited to or attend Pfizer meetings. We ask that you ensure that you are in a private location when joining the virtual meeting and that no unqualified persons or members of the public are able to hear or view the meeting content.

The meeting will be broadcast via a virtual platform enabling you to join the meeting from your own computer or mobile device and will allow you to receive audio and video streaming of the speaker presentations and pose questions to the speakers. You should not need to download any additional software onto your computer or mobile device in order to access the meeting however this is dependent on the device you are using.

REGISTER TO ATTEND:

Register to attend the meeting on the Pfizer Pro events site:

[please click here](#)

Or reply by email or telephone to: **Kerry Murphy** - Kerry.murphy@pfizer.com
- **07771 938257** to confirm your attendance at this meeting. Please include the meeting date and time in your response and provide an email address for further Joining Instructions to be sent to you.

Adverse events should be reported. Reporting forms and information can be found at <https://coronavirus-yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

Reference:

¹. PAXLOVID® Summary of Product Characteristics. Great Britain

Prescribing Information (PI) for Paxlovid® ▼ (nirmatrelvir/ritonavir) Great Britain <https://www.emcpi.com/pi/40758>

Your personal data that you provide to us will be processed by Pfizer for the purpose of managing your attendance at the meeting. We will share your personal data with our nominated agency who manage[s] our meeting registration and is under an obligation to process your personal data only for that purpose. To find out more about how Pfizer processes your personal data, including public disclosures of the transfers of value that you may receive from Pfizer, please refer to the Pfizer HCP Privacy Notice at <https://privacycenter.pfizer.com/en/hcp> If you have questions about our Privacy Notice, or if you would like to exercise any individual rights for example to review, correct, update, suppress, restrict or delete personal data that you have provided to us, or to opt out of any communications, please contact us at DataProtectionUK@Pfizer.com or write to the following address: Pfizer Limited, IPC 1-1, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS.